Alonso-Fernández A, García-Río F, Arias M A, Hernanz A, de la Peña M, Piérola J, Barceló A, López-Collazo E, Agustí A
Department of Pneumology, Hospital Universitario Son Dureta, Palma de Mallorca, Spain.
Thorax. 2009 Jul;64(7):581-6. doi: 10.1136/thx.2008.100537. Epub 2008 Dec 15.
Previous studies have presented contradictory data concerning obstructive sleep apnoea syndrome (OSAS), lipid oxidation and nitric oxide (NO) bioavailability. This study was undertaken to (1) compare the concentration of 8-isoprostane and total nitrate and nitrite (NOx) in plasma of middle-aged men with OSAS and no other known co-morbidity and healthy controls of the same age, gender and body mass index; and (2) test the hypothesis that nasal continuous positive airway pressure (CPAP) therapy attenuates oxidative stress and nitrate deficiency.
A prospective, randomised, placebo controlled, double-blind, crossover study was performed in 31 consecutive middle-aged men with newly diagnosed OSAS and 15 healthy control subjects. Patients with OSAS were randomised to receive sham CPAP or effective CPAP for 12 weeks. Blood pressure, urinary catecholamine levels and plasma 8-isoprostane and NOx concentrations were obtained before and after both treatment modalities.
Patients with OSAS had significantly higher 8-isoprostane levels (median (IQR) 42.5 (29.2-78.2) vs 20.0 (12.5-52.5) pg/ml, p = 0.041, Mann-Whitney test) and lower NOx levels (264 (165-650) vs 590 (251-1465) micromol/l, p = 0.022) than healthy subjects. Body mass index, blood pressure and urinary catecholamines were unchanged by CPAP therapy, but 8-isoprostane concentrations decreased (38.5 (24.2-58.7) pg/ml at baseline vs 22.5 (16.2-35.3) pg/ml on CPAP, p = 0.0001) and NOx levels increased (280 (177-707) vs 1373 (981-1517) micromol/l, p = 0.0001) after CPAP.
OSAS is associated with an increase in oxidative stress and a decrease in NOx that is normalised by CPAP therapy.
先前的研究关于阻塞性睡眠呼吸暂停综合征(OSAS)、脂质氧化和一氧化氮(NO)生物利用度给出了相互矛盾的数据。本研究旨在:(1)比较患有OSAS且无其他已知合并症的中年男性与年龄、性别和体重指数相同的健康对照者血浆中8-异前列腺素以及总硝酸盐和亚硝酸盐(NOx)的浓度;(2)检验鼻持续气道正压通气(CPAP)治疗可减轻氧化应激和硝酸盐缺乏这一假设。
对31名新诊断为OSAS的连续中年男性和15名健康对照者进行了一项前瞻性、随机、安慰剂对照、双盲、交叉研究。OSAS患者被随机分为接受假CPAP或有效CPAP治疗12周。在两种治疗方式前后均测量血压、尿儿茶酚胺水平以及血浆8-异前列腺素和NOx浓度。
与健康受试者相比,OSAS患者的8-异前列腺素水平显著更高(中位数(四分位间距)42.5(29.2 - 78.2)对20.0(12.5 - 52.5)pg/ml,p = 0.041,曼 - 惠特尼检验),而NOx水平更低(264(165 - 650)对590(251 - 1465)μmol/l,p = 0.022)。CPAP治疗对体重指数、血压和尿儿茶酚胺无影响,但CPAP治疗后8-异前列腺素浓度降低(基线时为38.5(24.2 - 58.7)pg/ml,CPAP治疗时为22.5(16.2 - 35.3)pg/ml,p = 0.0001),NOx水平升高(280(177 - 707)对1373(981 - 1517)μmol/l,p = 0.0001)。
OSAS与氧化应激增加和NOx降低有关,CPAP治疗可使其恢复正常。